At a glance
- Originator Otsuka Pharmaceutical
- Class Antibacterials; Cephems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 08 Jun 2001 This compound is still in active development
- 27 Jul 1995 New profile
- 27 Jul 1995 Preclinical development for Bacterial infections in Japan (Parenteral)